OrbiMed’s Big Fund Signals A Potential Return To Health For VCs
This article was originally published in The Pink Sheet Daily
The largest dedicated health care investor has closed a huge new fund, which came almost entirely from existing investors. OrbiMed isn’t the only firm capitalizing on the robust biotech IPO market. A few VCs are starting to take gains from IPO winners through secondary offerings.
You may also be interested in...
The IPO boom of 2013 is showing signs of slowing, while class of 2012 companies are seeing stock prices decline. Plus news on recent financings by Relypsa, Synta Pharmaceuticals, ArGEN-X and Karyopharm Therapeutics.
M&A has slowed for private biotechs this year, as acquisitions are overshadowed by IPOs. AstraZeneca is one of the few big biopharmas actively buying private biotechs. An option-to-acquire deal structure, amply employed by Celgene, is popping up lately.
After a slow August and early September, Wall Street is preparing for four biotech IPOs. Biotech IPOs have been on fire, outperforming even the vigorous biotech indices. But the question remains – can public investors get too much of a good thing?